Literature DB >> 6968743

Oxacillin for bacterial endophthalmitis: subconjunctival, intravenous, both, or neither?

M Barza, A Kane, J Baum.   

Abstract

We compared the intraocular concentrations of oxacillin given by continuous intravenous infusion, subconjunctival injection, or combined therapy in a rabbit model of Staphylococcus aureus endophthalmitis. At equilibrium during intravenous infusion, concentrations in the aqueous humor, cornea, and choroid-retina were 25% to 30% of the serum level; in contrast, vitreous levels were only 2% of the serum concentration. Subconjunctival injection produced extremely high levels in the cornea and aqueous and moderate concentrations in the choroid-retina; vitreous penetration remained poor (<1 microgram/ml). Combined therapy offered little advantage in terms of concentrations in the aqueous or cornea and had a modest effect on levels in the choroid-retina. Vitreous concentrations showed a striking relation to serum levels with all regimens, including subconjunctival ones; although this could have been fortuitous, it suggests an important role for the hematogenous route in this model. Only those modes of delivery producing serum concentrations greater than 50 micrograms/ml consistently resulted in vitreous levels greater than 0.4 microgram/ml. The optimal therapy of bacterial endophthalmitis may require direct intravitreal injection of antibiotic.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6968743

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  5 in total

1.  An intravitreal cannula system: long-term follow-up study.

Authors:  T Ishibashi; K Miki; R Patterson; S J Ryan
Journal:  Int Ophthalmol       Date:  1986-04       Impact factor: 2.031

2.  Intraocular cannula for chronic drug delivery. Method and clinical observation.

Authors:  K Miki; H Ohkuma; S J Ryan
Journal:  Int Ophthalmol       Date:  1985-09       Impact factor: 2.031

3.  Probenecid treatment enhances retinal and brain delivery of N-4-benzoylaminophenylsulfonylglycine: an anionic aldose reductase inhibitor.

Authors:  Gangadhar Sunkara; Surya P Ayalasomayajula; Jack DeRuiter; Uday B Kompella
Journal:  Brain Res Bull       Date:  2009-09-15       Impact factor: 4.077

4.  Cefsulodin pharmacokinetics and otitis media.

Authors:  P Federspil; W Schätzle; E Tiesler
Journal:  Arch Otorhinolaryngol       Date:  1982

5.  Penetration of ocular tissues and fluids by moxalactam in rabbits with staphylococcal endophthalmitis.

Authors:  A Kane; M Barza; J Baum
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.